Skip to main content
Premium Trial:

Request an Annual Quote

Cost-Benefit Analysis


A new study published in the New England Journal of Medicine — outlined here in this week's Cancer Minute NEJM roundup — shows that routine screening with low-dose computed tomography is associated with lower lung cancer mortality. But the cost of the test is likely to set off a debate about how an already "overburdened" healthcare system can afford the cost of additional screening on thousands of people a year, says Reuters' Bill Berkrot. While the study showed that low-dose CT screening could reduce lung cancer mortality by 20 percent, it also showed a high rate of false-positive results, Berkrot says. And while study results also show that roughly 300 people would have to be screened in order for one person to be saved, cancer experts say the study's results suggests that low-dose CT screening should become the standard of care for high-risk patients. But doctors are facing "an uphill battle to convince government programs and health insurers to pay for routine testing of millions of people," Berkrot says, even as officials search for ways to keep costs down. But while researchers agree that implementing screening in a broad population is expensive, they also say it's worth it to save lives.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.